Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
EMD Serono, a subsidiary of Germany's Merck KGaA, has appointed Drew Young as senior vice president of neurology and immunology, where he will lead the strategic direction of the US neurology and immunology franchise. 2 September 2014
Belgian cell therapy company TiGenix has appointed Marie Paule Richard as chief medical officer, and Mary Carmen Diez as its vice president of medical affairs and new product commercialization. 1 September 2014
French drug major Sanofi has replaced its North American chief Anne Whitaker with Jez Moulding, who will be head of the region’s pharma business following a senior management role in Japan and Asia Pacific. 28 August 2014
Mergers and acquisitions may excite the markets and shareholders on both sides but their record of success in delivering the anticipated benefits is not good, writes Stephen Archer, founder of Spring Partnerships. 19 August 2014
As big data plays an increasing role in drug development and clinical trials, The Pharma Letter’s Bethany Rutter spoke to Richard Young, vice president, mid-market EMEA at Medidata, which provides clinical research organizations and companies with highly advanced technological tools for planning and managing clinical trials. 15 August 2014
Coming from her position as president of Sanofi’s North American pharma division, Anne Whitaker has been named chief executive of Synta Pharmaceuticals. 12 August 2014
Astellas Pharma EMEA, the regional headquarters of Japanese drug major Astellas Pharma, has appointed Simon Dew as chief strategy officer. 7 August 2014
The pharmaceutical sector is still reeling from the latest fines imposed by the European Competition Commission as part of its crackdown on so-called ‘pay-for-delay’ agreements. As a result, such practices could be used less frequently in the future but they are unlikely to disappear altogether, according to patent and trade mark attorneys Withers & Rogers. 1 August 2014
In an interview with The Pharma Letter, Thomas Hein, senior vice president of commercial and regulatory affairs for German privately-owned company Hermes Pharma, tells us about how the company is working closely with eight of the world's top 15 pharma companies on its user-friendly dosage forms. 28 July 2014
Jan-Anders Karlsson, chief executive and director of UK-based biotechnology company Verona Pharma, has revealed his insights in a new video. 28 July 2014
Quebec-based cardiovascular drug development specialist Milestone Pharmaceuticals has announced the appointment of Francis Plat as chief medical officer. He is a cardiologist with extensive experience in cardio drug development. 21 July 2014
US-based Neurotrope, developers of diagnostic and therapeutic technologies for the treatment of neurodegenerative diseases, has announced the appointment of co-chairmen Charles Ramat and Paul Freiman as co-chief executives on an interim basis. 21 July 2014
US-based drug development and discovery company Aptuit has appointed Paul Overton as executive vice president, business development and marketing. He is now responsible for all of Aptuit’s sales and marketing activities. 16 July 2014
US-based clinical-stage biopharma company Xencor has announced the appointment of Kurt Gustafson to its board of directors. He will also serve as chair of the audit and compensation committees for the company which develops engineer monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. 15 July 2014